WSJ -- Genzyme, the biotech that is juggling manufacturing problems and a proxy fight with Carl Icahn, is open to selling off some of its noncore businesses, its CEO said in a briefing at Health Blog HQ. Here’s the Dow Jones Newswires story about the chat.
